Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity [Yahoo! Finance]
Structure Therapeutics Inc. - American Depositary Shares (GPCR)
Company Research
Source: Yahoo! Finance
developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that it has initiated a first-in-human Phase 1 clinical study of ACCG-2671, the company's lead oral small molecule amylin receptor agonist for the treatment of obesity. ACCG-2671 was designed via the company's next generation structure-based drug discovery platform to harness the established metabolic benefits of amylin biology in an oral, once-daily small molecule, with the potential to improve scalability, combinability, and patient access. “We believe amylin-based therapies are poised to become an important next-generation component of the treatment landscape for obesity and related conditions. Powered by our differentiated GPCR structure-based drug discovery platform, we have efficiently advanced ACCG-2671 into the clinic as the industry's most advanced oral small molecule amylin therapy,” said Xichen Lin, Ph.D., Chief Scientific Officer of Structure Therapeutics. “
Show less
Read more
Impact Snapshot
Event Time:
GPCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GPCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GPCR alerts
High impacting Structure Therapeutics Inc. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GPCR
News
- Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of ObesityGlobeNewswire
- Structure Therapeutics (NASDAQ:GPCR) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=GPCR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- Structure Therapeutics (NASDAQ:GPCR) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- Structure Therapeutics (NASDAQ:GPCR) had its price target raised by analysts at Citizens Jmp from $87.00 to $120.00. They now have a "market outperform" rating on the stock.MarketBeat
- Structure Therapeutics (NASDAQ:GPCR) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
GPCR
Sec Filings
- 12/10/25 - Form 8-K
- 12/10/25 - Form 424B5
- 12/10/25 - Form 4
- GPCR's page on the SEC website